Awakn Life Sciences Corp.
AWKN
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.70K | 8.00K | 15.20K | 16.20K | 21.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.70K | 8.00K | 15.20K | 16.20K | 21.30K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.70K | 8.00K | 15.20K | 16.20K | 21.30K |
| SG&A Expenses | 206.80K | 280.40K | 333.60K | 450.00K | 374.50K |
| Depreciation & Amortization | 3.30K | 3.40K | 3.50K | 3.50K | 4.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 348.30K | 433.30K | 401.60K | 640.10K | 518.30K |
| Operating Income | -345.60K | -425.30K | -386.30K | -624.00K | -497.00K |
| Income Before Tax | -275.50K | -263.60K | -401.50K | -974.30K | -476.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -275.50K | -263.60K | -401.50K | -974.30K | -476.60K |
| Earnings from Discontinued Operations | -- | -- | -- | 282.60K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -275.50K | -263.60K | -401.50K | -691.70K | -476.60K |
| EBIT | -345.60K | -425.30K | -386.30K | -624.00K | -497.00K |
| EBITDA | -342.30K | -421.90K | -382.80K | -620.40K | -492.40K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 35.08M | 33.92M | 39.27M | 31.60M | 30.51M |
| Average Diluted Shares Outstanding | 35.08M | 33.92M | 39.27M | 31.60M | 30.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |